SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
This Quarter Return
+5.7%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$2.45B
AUM Growth
+$2.45B
(+3.4%)
Cap. Flow
+$258M
Cap. Flow
% of AUM
10.51%
Top 10 Holdings %
Top 10 Hldgs %
45.17%
Holding
110
New
9
Increased
24
Reduced
21
Closed
11
Top Buys
| 1 |
UnitedHealth
UNH
|
$74.5M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$41.6M |
| 3 |
Biohaven
BHVN
|
$41.5M |
| 4 |
Apple
AAPL
|
$39.3M |
| 5 |
Sysco
SYY
|
$37.2M |
Top Sells
| 1 |
argenx
ARGX
|
$48M |
| 2 |
Cigna
CI
|
$43.7M |
| 3 |
McKesson
MCK
|
$32M |
| 4 |
Verizon
VZ
|
$23.5M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$22.8M |
Sector Composition
| 1 | Healthcare | 65.51% |
| 2 | Technology | 11.21% |
| 3 | Communication Services | 6.91% |
| 4 | Consumer Discretionary | 6.1% |
| 5 | Financials | 3.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Alnylam Pharmaceuticals
ALNY
$58.6B
| $9.14M | 0.34% |
37,624
+4,964
| +15% | +$1.21M |
|
52
GE HealthCare
GEHC
$33B
| $5.84M | 0.21% |
75,000
| – | – |
|
|
MRNS
53
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $4.47M | 0.16% |
3,820,012
-1,288,508
| -25% | -$1.51M |
|
54
Teva Pharmaceuticals
TEVA
$21.5B
| $4.36M | 0.16% |
268,100
| – | – |
|
55
Kezar Life Sciences
KZR
$28.5M
| $4.3M | 0.16% |
716,759
| – | – |
|
56
Danaher
DHR
$143B
| $4.1M | 0.15% |
16,427
| – | – |
|
57
Thermo Fisher Scientific
TMO
$183B
| $4.01M | 0.15% |
7,260
| – | – |
|
58
Exact Sciences
EXAS
$9.33B
| $3.98M | 0.15% |
+94,100
| New | +$3.98M |
|
59
Elanco Animal Health
ELAN
$8.62B
| $3.66M | 0.13% |
253,600
-253,600
| -50% | -$3.66M |
|
60
Abbott
ABT
$230B
| $3.48M | 0.13% |
33,520
| – | – |
|
61
Gilead Sciences
GILD
$140B
| $3.48M | 0.13% |
50,700
| – | – |
|
62
Kenvue
KVUE
$39.2B
| $3.12M | 0.11% |
171,596
| – | – |
|
|
MOLN
63
Molecular Partners
MOLN
$139M
| $2.89M | 0.11% |
400,000
| – | – |
|
64
Cencora
COR
$57.2B
| $2.81M | 0.1% |
12,488
| – | – |
|
65
Mettler-Toledo International
MTD
$26.1B
| $2.74M | 0.1% |
1,964
| – | – |
|
66
Spyre Therapeutics
SYRE
$1.02B
| $2.52M | 0.09% |
107,310
-55,085
| -34% | -$1.3M |
|
67
Intuitive Surgical
ISRG
$158B
| $2.31M | 0.09% |
5,200
| – | – |
|
68
Tourmaline Bio
TRML
$645M
| $1.61M | 0.06% |
125,000
| – | – |
|
|
69
Cigna
CI
$80.2B
| $1.59M | 0.06% |
4,800
-132,339
| -96% | -$43.7M |
|
70
Avantor
AVTR
$8.74B
| $1.52M | 0.06% |
71,850
| – | – |
|
71
IQVIA
IQV
$31.4B
| $1.52M | 0.06% |
7,175
| – | – |
|
72
Stryker
SYK
$149B
| $1.48M | 0.05% |
4,360
| – | – |
|
73
Medtronic
MDT
$118B
| $1.37M | 0.05% |
17,460
| – | – |
|
74
Galapagos
GLPG
$2.06B
| $1.17M | 0.04% |
47,200
| – | – |
|
75
Natera
NTRA
$23B
| $1.09M | 0.04% |
10,100
-14,500
| -59% | -$1.57M |
|